Mylan
Mylan N.V., founded in 1961, was a global generic and specialty pharmaceutical company that became part of Viatris Inc. in 2020 after merging with Pfizer's Upjohn. It serves healthcare systems, hospitals, and retail pharmacies across 165+ countries with 1,400+ medicines.
- Company typePrivate
- Founded1961
- HeadquartersHyderabad, India
- Headcount5,001–10,000
- GTM typeB2B
- OfferingHardware or Manufacturing
What Mylan does
Mylan N.V. was a global generic and specialty pharmaceutical company founded in 1961 and headquartered in the Netherlands, with its largest operating base in Hyderabad, India. From inception through 2020, the company built a portfolio spanning oral solid doses, sterile injectables, complex generics, biosimilars, and active pharmaceutical ingredients, manufacturing across 26 global facilities with combined annual dose capacity exceeding 80 billion units and a product portfolio of 1,400+ medicines spanning oncology, immunology, chronic disease, and acute care therapeutic areas. Core technical capabilities centered on complex generics manufacturing, biosimilar development (including G-CSF biosimilars), and generic injectable production, supported by R&D centers in Hyderabad (APIs and OSDs) and Bangalore (injectables).
On November 16, 2020, Mylan N.V. combined with Pfizer's Upjohn unit through an all-stock transaction valued at approximately $40 billion to form Viatris Inc., at which point Mylan N.V. was delisted from NASDAQ and became a wholly-owned subsidiary. The combined entity operates in 165+ countries through a hybrid go-to-market combining direct commercial operations in major markets, hospital and retail pharmacy distribution channels, and government/public health system contracts. Mylan's revenue streams historically comprised commodity generic pharmaceuticals, higher-margin complex generics and biosimilars, and branded established medicines inherited from Upjohn; standalone Mylan revenue is no longer separately disclosed within Viatris consolidated reporting.
Mylan firmographics
Firmographics- Name
- Mylan
- Legal name
- Mylan N.V.
- Website
- https://mylan.in
- Company type
- Private
- Founded year
- 1961
- Operating status
- Acquired
- Headcount range
- 5,001–10,000 employees
- Short description
- Mylan N.V., founded in 1961, was a global generic and specialty pharmaceutical company that became part of Viatris Inc. in 2020 after merging with Pfizer's Upjohn. It serves healthcare systems, hospitals, and retail pharmacies across 165+ countries with 1,400+ medicines.
- Ownership category
- akta.pro rank
Mylan industry classification
Industry- Product category
- Generic Pharmaceuticals
- NAICS
- Pharmaceutical and Medicine Manufacturing (32541), Pharmaceutical Preparation Manufacturing (325412), Pharmaceutical and Medicine Manufacturing (3254)
- SIC
- Pharmaceutical Preparations (2834)
- akta.pro primary industry
- Generic Finished Dosage Form (FDF) Manufacturing (HLAIABAH)
- akta.pro secondary industries
- Sterile Injectable Generics (HLAIABAC), Fill-Finish & Aseptic Drug Product Manufacturing (Biologics/ATMP) (HLAGAGAG)
Keywords
Where Mylan is headquartered
LocationHeadquarters
- HQ city
- Hyderabad
- HQ country
- India
- HQ region
- Asia
Offices4 records
Markets served
Mylan business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Supply Chain, Operations, Personnel, Technology or R&D, Infrastructure, Marketing or Sales
Revenue model
- Generic Pharmaceuticals: Revenue from selling generic pharmaceutical products including oral solid doses and injectable medicines across global markets
- Complex Generics and Biosimilars: Revenue from complex generic drugs and biosimilars which command higher margins than simple generics, driven by patent expirations of major biologics
- Branded Established Medicines: Revenue from branded established medicines following the merger with Pfizer's Upjohn unit
Go-to-market motion3 records
Distribution channels4 records
Marketing channels3 records
Mylan product offering
Product offeringCore offering
Mylan N.V. developed, manufactured, and distributed a broad portfolio of generic, complex generic, specialty, and biosimilar pharmaceutical products. Following the 2020 combination with Pfizer's Upjohn unit, the Mylan business now operates as part of Viatris Inc., producing oral solid doses, injectables, APIs, and biosimilars across therapeutic areas such as oncology, immunology, diabetes, and chronic disease, with global manufacturing and R&D operations centered in India (Hyderabad and Bangalore).
Product overview
Mylan N.V., now part of Viatris Inc. following the 2020 merger with Pfizer's Upjohn unit, operates as a global generics, complex generics, and biosimilars company. The company provides a wide range of pharmaceutical products across therapeutic areas including zoledronic acid for bone conditions, herpes treatments, G-CSF biosimilars for neutropenia, docusate sodium, transdermal scopolamine, sucralfate API, dalteparin sodium injection, OTC drugs, plaque psoriasis treatments, and acne medicines. Mylan/Viatris operates manufacturing facilities in India producing oral solid doses and injectables, with R&D centers in Hyderabad and Bangalore. The company operates across 165+ countries with approximately 1,400 medicines.
Differentiator
Problem solved
Functional benefit
Products and services
- Zoledronic Acid
- Herpes Treatment Drugs
- G-CSF and G-CSF Biosimilars
- Docusate Sodium
- Transdermal Scopolamine
- Sucralfate API
- Dalteparin Sodium Injection
- Over The Counter (OTC) Drugs
- Plaque Psoriasis Treatment
- Acne Medicine
- Neurogenic Bladder Infections Treatment
Quantifiable outcome
- One of the largest global generic pharmaceutical companies with top-tier market position
- +1 more outcomes
Companies that use Mylan
Customer profileNamed customers3 records
Segments4 records
Ideal customer profiles4 records
Mylan technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature3 records
Mylan partnerships and signals
Strategic signalPartnerships
Five partnerships are on record, tiered minor and major.
- Mankind PharmaminorMankind Pharma received a royalty-free, non-exclusive U.S. license to market a generic version of YUPELRI starting April 23, 2039, as part of settlement resolving Hatch-Waxman patent litigation.
- Biocon LtdmajorMylan Inc. (Viatris) sold its minority stake in Biocon Biologics Ltd to Biocon Ltd for $200 million cash as part of a $400 million two-part transaction, completing the buyback and enabling full integration of Biocon Biologics.
- Pfizer Inc. (Upjohn)majorMylan N.V. and Pfizer Inc. completed a global transaction combining Mylan with Upjohn (Pfizer's off-patent branded and generic established medicines business) to create Viatris Inc., forming one of the largest global pharmaceutical companies.
- Natco PharmaminorNatco/Mylan partnership for GLP-1 drug development in India's weight loss and diabetes-management market competing against branded products.
- Cipla, Fresenius Kabi, Pfizer, Hetero, AlkemminorPharmaceutical companies including Mylan sought government price increase for chemotherapy drugs Cisplatin and Carboplatin citing rising raw material costs linked to conflict in West Asia.
Scale indicators6 records
Recent moves7 records
Expansion highlights5 records
Mylan competitors and assessment
Company assessmentMarket position
Weaknesses4 records
Competitive moat5 records
Key risks5 records
Key highlights7 records
Customer concentration
Mylan social profiles
Digital presenceMylan financial estimates
Financial estimateRevenue estimate
Valuation estimate
Mylan leadership team
Management profileNumber of profiles
Mylan subsidiaries and ownership
Company hierarchySubsidiaries1 record
Mylan funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Mylan M&A and investment
M&A and investmentM&A10 records
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Mylan
What does Mylan do?
Mylan N.V. developed, manufactured, and distributed a broad portfolio of generic, complex generic, specialty, and biosimilar pharmaceutical products. Following the 2020 combination with Pfizer's Upjohn unit, the Mylan business now operates as part of Viatris Inc., producing oral solid doses, injectables, APIs, and biosimilars across therapeutic areas such as oncology, immunology, diabetes, and chronic disease, with global manufacturing and R&D operations centered in India (Hyderabad and Bangalore).
Is Mylan a public or private company?
Mylan is a private company. It is classified as corporate owned and is currently acquired.
When was Mylan founded?
Mylan was founded in 1961. It employs 5,001 to 10,000 people.
Where is Mylan based?
Mylan is headquartered in Hyderabad, India, in the Asia region.
How does Mylan make money?
Three revenue lines are on record. Generic Pharmaceuticals are the primary driver. The others are complex Generics and Biosimilars and branded Established Medicines.
Does Mylan have an API?
No public API is recorded for Mylan.
What industry is Mylan in?
Mylan's product category is Generic Pharmaceuticals. Its primary akta.pro industry code is HLAIABAH, Generic Finished Dosage Form (FDF) Manufacturing, with a secondary code of HLAIABAC, Sterile Injectable Generics. Its NAICS code is 32541 and its SIC code is 2834.